Literature DB >> 4059392

The effects of entorhinal cortex lesions on type 1 and type 2 theta.

C P Montoya, R S Sainsbury.   

Abstract

The effects of bilateral entorhinal cortex lesions on type 1 and type 2 theta generation in the guinea pig were studied in the chronic preparation. EEG recordings from dentate generator zones demonstrated a decrease in the relationship between ongoing type 1 motor movements and theta generation. Before lesioning theta activity accompanied type 1 behaviors (i.e., walking and head movements) in 100% of the samples, while subsequent to lesioning theta activity was present in only 58% of the samples. In addition, prior to lesioning, type 2 theta was present in 100% of the samples taken during immobile sensory processing, e.g., tactile stimulation, while after lesioning type 2 theta was present in only 34% of the samples. Type 2 theta is selectively sensitive to disruption by atropine sulfate. In the present experiment atropine sulfate eliminated all theta activity after entorhinal lesions. Consequently as no type 1 theta appeared to be present it was argued that the entorhinal cortex is a critical route for type 1 theta. However, as the behavioral and sensory correlates of both type 1 and type 2 theta were disrupted it was suggested that the entorhinal cortex is an integral part of both systems.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4059392     DOI: 10.1016/0031-9384(85)90183-0

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  2 in total

1.  Theta phase coding in a network model of the entorhinal cortex layer II with entorhinal-hippocampal loop connections.

Authors:  Jun Igarashi; Hatsuo Hayashi; Katsumi Tateno
Journal:  Cogn Neurodyn       Date:  2006-10-31       Impact factor: 5.082

2.  Hippocampus and Entorhinal Cortex Recruit Cholinergic and NMDA Receptors Separately to Generate Hippocampal Theta Oscillations.

Authors:  Zhenglin Gu; Georgia M Alexander; Serena M Dudek; Jerrel L Yakel
Journal:  Cell Rep       Date:  2017-12-19       Impact factor: 9.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.